Hemodynamic Change of Coronary Atherosclerotic Plaque After Evolocumab Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-07-30

Study Completion Date

2023-02-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Compelling evidences indicate that lipid-lowering therapy can reduce the high-risk plaque feathers and improve the coronary flow reserve. This study is going to investigate the change of lesion-specific hemodynamic significance as determined by ML(Machine Learning)-based CT-FFR (Computed Tomography-Fractional Flow Reserve)after Evolocumab treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravascular Imaging Evaluated Calcified Nodule China Registry

NCT07262359

Coronary Artery Disease Coronary Artery Atherosclerosis Coronary Calcified Nodules +1 more

NOT_YET_RECRUITING

Diagnostic Performance of Fractional Flow Reserve Derived From Coronary CT Angiography

NCT04426396

Coronary Artery Disease

COMPLETED

Imaging and Biomarkers of Atherosclerosis in Patients With Stable or Unstable Coronary Artery Disease

NCT01186666

Atherosclerosis Coronary Artery Disease Acute Coronary Syndrome

COMPLETED NA

Follow-up With CT-FFR in CHD Patients After DCB

NCT04664439

Coronary; Ischemic

UNKNOWN NA

Coronary Atherosclerosis Disease Early Identification and Risk Stratification by Noninvasive Imaging

NCT03518437

Coronary Artery Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atherosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Enrolled Cohort

200 selected patients will be recruited, who have diagnosed with coronary atherosclerosis disease(stenotic extent from 50% to 69% on major epicardial arteries) by coronary computed tomography angiography(CCTA). Every two weeks, these patients will be treated with Elococumab Injection (1ml:140mg),ih.This therapy will last for one year.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1.baseline CCTA revealed at least one lesion with stenotic extent from 50% to 69% on major epicardial arteries (diameter ≧2 mm);
* 2.patients were referred for optimal medical treatment;
* 3.patients agreed to undergo follow-up CCTA at 1-year interval.

Exclusion Criteria

* 1.patients had previous history of myocardial infarction or coronary revascularization;
* 2.patients were contraindicated to the usage of iodine contrast media;
* 3.image quality of baseline or follow-up CCTA was severely impaired (in presence of severe artifact, non-diagnostic);
* 4.patients withdrew the informed consents during follow-up;
* 5.patients experienced major adverse cardiac events during follow-up;
* 6.patients refused to undergo follow-up CCTA;
* 7.lost follow-up

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No